FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include Patients with PSMA Positive mCRPC By Ogkologos - April 25, 2025 773 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PSMAfore study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR What could DeepMind ‘solving’ the protein folding problem mean for cancer... December 23, 2020 Group Dressed as Breasts Gathers to Protest Facebook’s Censorship of Areola... September 2, 2021 Adding Upfront SRS to CNS-penetrant TKI Improves Time-to-CNS Progression and Local... August 27, 2024 Improving Cancer Immunotherapy: Overcoming the Problem of ‘Exhausted’ T Cells July 18, 2019 Load more HOT NEWS FDA Approves Melphalan As a Liver-Directed Treatment for Uveal Melanoma First-Line Treatment with Atezolizumab Associated with Improved OS in Patients with... Neoadjuvant Atezolizumab Plus Chemotherapy Is Safe and Has Promising Activity in... Help Desk for Oncologists Treating People with a Rare Leukemia Pays...
